Slipped Capital Femoral Epiphysis, commonly known as SCFE, is a condition that affects the hip joint in young adolescents. It occurs when the growth plate of the femur (thigh bone) slips out of place from the ball at the top of the femur. Although it is not a common ailment, early diagnosis and treatment are crucial to prevent long-term complications such as osteoarthritis and avascular necrosis. In this blog post, we will delve into everything medical professionals should know about SCFE - from its causes and symptoms to its treatment options and long-term effects. So strap on your seatbelts and let's dive deep into understanding SCFE!
Slipped Capital Femoral Epiphysis (SCFE) is a condition that requires immediate medical attention. The main goal of treatment for SCFE is to stabilize the slipped epiphysis and prevent further slippage.
Surgery is typically required for most cases of SCFE, which involves placing screws or pins in the affected hip joint to hold it in place. This procedure aims to reduce pain and restore normal movement in the hip joint.
After surgery, patients will need to undergo physical therapy sessions to help them regain strength and flexibility in their hip muscles. Physical therapy also helps improve balance and mobility while avoiding any unnecessary strain on the affected area.
Slipped Capital Femoral Epiphysis (SCFE) is a condition that affects the hip joint of children and teenagers. While it can be treated, there are some long-term effects that patients need to take note of.
One long-term effect of SCFE is arthritis. Due to the abnormal growth and development of the hip joint during SCFE, patients may experience pain and stiffness in their hips as they grow older. This can eventually lead to difficulty with mobility and daily activities.
In severe cases, avascular necrosis (AVN) can occur which means loss of blood supply to bone tissue leading to its death. If AVN does develop, it could require surgical intervention such as a total joint replacement procedure.
Another potential consequence is leg length discrepancy where one leg appears shorter than the other due to differences in growth rates between both legs after treatment or surgery for SCFE.
Slipped capital femoral epiphysis is a serious condition that can cause long-term effects if not treated promptly. Medical professionals should be aware of the signs and symptoms of SCFE in order to diagnose it early and recommend appropriate treatment options.
Early diagnosis and intervention can help prevent further complications such as avascular necrosis or degenerative arthritis. Treatment options include surgical intervention, physical therapy, and medication management.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation